Ulixertinib
As of the edition of 20 October 2026, Ulixertinib is a small molecule: stopped in 2025; acts on MAPK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 18, 4 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Ulixertinib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAPK1 | Mitogen-activated protein kinase 1 | P28482 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 6 | 2 | 3 | 1 |
| Phase 2 | 11 | 2 | 6 | 3 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BioMed Valley Discoveries | Lead sponsor of trials | 2013 to now |
| xCures | Lead sponsor of trials |